FTC Backs FDA Draft Guidance on Interchangeable Biosimilar Drugs

The Federal Trade Commission (FTC) has expressed support for the FDA's recent draft guidance on interchangeable biosimilar drugs, which the agency says could significantly enhance patient access to more affordable prescription medications. The FDA’s draft guidance proposes changes that could streamline the approval process for biosimilars, making it easier for these drugs to be substituted for more expensive brand-name biologics.

Biologic drugs, known for their complex and large molecular structures, are often used to treat serious medical conditions. However, these medications are among the most expensive on the market, placing a significant financial burden on patients, the FDA stated in its guidance. Biosimilar drugs, which are similar to generic drugs, offer a cost-effective alternative. They are designed to treat the same conditions as their brand-name counterparts with no clinically meaningful differences in terms of safety and effectiveness.

A key aspect of the FDA's draft guidance is the removal of the previous requirement for biosimilar drug applicants to submit clinical switching studies to prove that their product is interchangeable with the reference biologic drug. Instead, biosimilar applicants can now provide a rationale, supported by existing data from the biologic license application, to demonstrate interchangeability. This change would allow pharmacists to substitute an interchangeable biosimilar for a biologic without needing prescriber intervention, potentially expediting patient access to these lower-cost options.

The FTC stated it believes that the increased flexibility in the approval process will reduce the time and costs associated with demonstrating interchangeability. The FTC also argues that the new guidance will help to clarify any lingering marketplace confusion regarding the safety and efficacy of biosimilars, which has been a barrier to their broader acceptance and use.

If implemented, the FDA's draft guidance could pave the way for a more competitive marketplace for biologic products by increasing the number of biosimilars designated as interchangeable. This, in turn, could drive down prices and expand choices for patients, the FTC stated.